- Home
- SLM vs NUVL Comparison
SLM vs NUVL Comparison
Compare SLM & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLM
- NUVL
- Stock Information
- Founded
- SLM 1972
- NUVL 2017
- Country
- SLM United States
- NUVL United States
- Employees
- SLM N/A
- NUVL N/A
- Industry
- SLM Finance: Consumer Services
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- SLM Finance
- NUVL Health Care
- Exchange
- SLM Nasdaq
- NUVL Nasdaq
- Market Cap
- SLM 5.9B
- NUVL 5.6B
- IPO Year
- SLM N/A
- NUVL 2021
- Fundamental
- Price
- SLM $27.75
- NUVL $73.48
- Analyst Decision
- SLM Buy
- NUVL Strong Buy
- Analyst Count
- SLM 11
- NUVL 8
- Target Price
- SLM $30.45
- NUVL $115.50
- AVG Volume (30 Days)
- SLM 2.7M
- NUVL 686.7K
- Earning Date
- SLM 04-24-2025
- NUVL 05-08-2025
- Dividend Yield
- SLM 1.87%
- NUVL N/A
- EPS Growth
- SLM N/A
- NUVL N/A
- EPS
- SLM 2.78
- NUVL N/A
- Revenue
- SLM $1,449,130,000.00
- NUVL N/A
- Revenue This Year
- SLM $12.94
- NUVL N/A
- Revenue Next Year
- SLM $9.65
- NUVL N/A
- P/E Ratio
- SLM $9.97
- NUVL N/A
- Revenue Growth
- SLM N/A
- NUVL N/A
- 52 Week Low
- SLM $19.39
- NUVL $55.54
- 52 Week High
- SLM $32.65
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- SLM 51.25
- NUVL 54.91
- Support Level
- SLM $25.93
- NUVL $71.60
- Resistance Level
- SLM $27.17
- NUVL $74.28
- Average True Range (ATR)
- SLM 1.39
- NUVL 4.86
- MACD
- SLM 0.25
- NUVL 1.08
- Stochastic Oscillator
- SLM 85.28
- NUVL 95.73
About SLM SLM Corporation
SLM Corp is the largest student lender in the country. It makes and holds student loans through the guaranteed Federal Family Education Loan Program as well as through private channels. It also engages in debt-management operations, including accounts receivable and collections services, and runs college savings programs.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.